|
gptkbp:instanceOf
|
gptkb:small_molecule
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2011
|
|
gptkbp:ATCCode
|
L01XE15
|
|
gptkbp:brand
|
gptkb:Zelboraf
|
|
gptkbp:CASNumber
|
918504-65-1
|
|
gptkbp:chemicalFormula
|
C23H18ClF2N3O3S
|
|
gptkbp:contraindication
|
hypersensitivity to vemurafenib
|
|
gptkbp:developedBy
|
gptkb:Plexxikon
|
|
gptkbp:eliminationHalfLife
|
57 hours
|
|
gptkbp:indication
|
unresectable or metastatic melanoma with BRAF V600E mutation
|
|
gptkbp:KEGGID
|
D09716
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
gptkb:BRAF_inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
489.92 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1787
gptkb:DB08881
42611257
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:cutaneous_squamous_cell_carcinoma
fatigue
rash
photosensitivity
arthralgia
|
|
gptkbp:synonym
|
gptkb:PLX4032
|
|
gptkbp:target
|
gptkb:BRAF_V600E_mutation
|
|
gptkbp:UNII
|
NJU539730N
|
|
gptkbp:usedFor
|
treatment of melanoma
|
|
gptkbp:bfsParent
|
gptkb:RAF_kinase
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vemurafenib
|